national priority review voucher
Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study
Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial